Trials / Completed
CompletedNCT00676091
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Brazil
A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Brazil
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 354 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 28 Days – 54 Days
- Healthy volunteers
- Accepted
Summary
The purpose of this study will be to analyze 13-valent pneumococcal vaccine given to healthy infants in Brazil for safety and tolerability, and to determine the immune response to the vaccines.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) | |
| BIOLOGICAL | 7-Valent Pneumococcal Conjugate Vaccine (7vPnc) |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2008-05-12
- Last updated
- 2011-08-08
- Results posted
- 2010-10-15
Locations
4 sites across 1 country: Brazil
Source: ClinicalTrials.gov record NCT00676091. Inclusion in this directory is not an endorsement.